A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Reeves, Rachel Mvan Wijhe, Maarten
Lehtonen, Toni
Stona, Luca
Teirlinck, Anne C
Vazquez Fernandez, Liliana
Li, You
Osei-Yeboah, Richard
Fischer, Thea K
Heikkinen, Terho
van Boven, Michiel
Bøås, Håkon
Donà, Daniele
Barbieri, Elisa
Campbell, Harry
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.Published in
The Journal of infectious diseases 2022; 226(Suppl 1):S110-S116PMID
35333332ae974a485f413a2113503eed53cd6c53
10.1093/infdis/jiac059
Scopus Count
Collections
Related articles
- Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
- Authors: Narayan O, Bentley A, Mowbray K, Hermansson M, Pivonka D, Kemadjou EN, Belsey J
- Issue date: 2020 Dec
- Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
- Authors: Wang D, Bayliss S, Meads C
- Issue date: 2011 Jan
- Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
- Authors: Ratti C, Greca AD, Bertoncelli D, Rubini M, Tchana B
- Issue date: 2023 Jan 11
- Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
- Authors: Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P, Composs Investigators
- Issue date: 2002 Jun
- A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
- Authors: Ambrose CS, Chen X, Kumar VR
- Issue date: 2014